Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Total 13F shares
-
54,291,633
-
Share change
-
-1,091,278
-
Total reported value
-
$80,994,102
-
Put/Call ratio
-
7.7%
-
Price per share
-
$1.49
-
Number of holders
-
73
-
Value change
-
-$2,237,000
-
Number of buys
-
22
-
Number of sells
-
40
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2022
As of 31 Mar 2022,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,291,633 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, PURA VIDA INVESTMENTS, LLC, BlackRock Inc., VANGUARD GROUP INC, ORBIMED ADVISORS LLC, Defender Capital, LLC., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, Nuveen Asset Management, LLC, and Schonfeld Strategic Advisors LLC.
This page lists
73
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.